4basebio (4BB)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

1,120.00p
   
  • Change Today:
      50.00p
  • 52 Week High: 1,120.00
  • 52 Week Low: 500.00
  • Currency: UK Pounds
  • Shares Issued: 12.81m
  • Volume: 849
  • Market Cap: £143.42m

Deal with Barclays    Trade now with Barclays Stockbrokers

Growth Ratings

EPS Growth shows the relative growth of a company's earnings over the last year.

The rise in total monies receivable for goods / services sold before expenses.

1yr EPS Growth Not Available
1yr Revenue Growth
80.75% below the market average80.75% below the market average80.75% below the market average80.75% below the market average80.75% below the market average
48.57% below the sector average48.57% below the sector average48.57% below the sector average48.57% below the sector average48.57% below the sector average

Income Ratings

The percentage of the share price that a company pays out as dividends over a year.

The percentage change from the previous year in the dividend paid on each share.

Dividend Yield Not Available
1yr DPS Growth Not Available

Valuation Ratings

The share price as a ratio of revenue per share.

The share price as a ratio of net asset value.

Price Sales Ratio
96.91% above the market average96.91% above the market average96.91% above the market average96.91% above the market average96.91% above the market average
93.33% above the sector average93.33% above the sector average93.33% above the sector average93.33% above the sector average93.33% above the sector average
Price Book Ratio
96.83% below the market average96.83% below the market average96.83% below the market average96.83% below the market average96.83% below the market average
95.92% below the sector average95.92% below the sector average95.92% below the sector average95.92% below the sector average95.92% below the sector average

Performance Ratings

In percentage total change in share price over 30 days.

In percentage total change in share price over 3 months.

Price Chg 30d
85.62% above the market average85.62% above the market average85.62% above the market average85.62% above the market average85.62% above the market average
78.95% above the sector average78.95% above the sector average78.95% above the sector average78.95% above the sector average78.95% above the sector average
Price Chg 3m
97.15% above the market average97.15% above the market average97.15% above the market average97.15% above the market average97.15% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average

Technical Ratings

The Relative Strength Index measures a share price relative to itself and its recent history.

Momentum is an oscillator that measures the rate of price change.

RSI
86.71% above the market average86.71% above the market average86.71% above the market average86.71% above the market average86.71% above the market average
88.68% above the sector average88.68% above the sector average88.68% above the sector average88.68% above the sector average88.68% above the sector average
Momentum 20
97.37% above the market average97.37% above the market average97.37% above the market average97.37% above the market average97.37% above the market average
96.23% above the sector average96.23% above the sector average96.23% above the sector average96.23% above the sector average96.23% above the sector average

Management Ratings

Operating Margin is profit as a percentage of sales.

Return on capital employed measures the return from invested and borrowed capital.

Operating Margin
94.64% below the market average94.64% below the market average94.64% below the market average94.64% below the market average94.64% below the market average
72.97% below the sector average72.97% below the sector average72.97% below the sector average72.97% below the sector average72.97% below the sector average
ROCE Not Available

Profitability Ratings

Earnings per share, the company's profitability expressed on a per share basis.

Analysts' estimates of future EPS for the next 2 years.

EPS
94.9% below the market average94.9% below the market average94.9% below the market average94.9% below the market average94.9% below the market average
96.3% below the sector average96.3% below the sector average96.3% below the sector average96.3% below the sector average96.3% below the sector average
Forecast EPS Not Available

Profit/Loss Ratings

Monies produced from sales of goods and services after trade discounts, VAT, etc.

Operating Profit is the profit after deducting operating costs from gross profits.

Turnover
90.12% below the market average90.12% below the market average90.12% below the market average90.12% below the market average90.12% below the market average
78.38% below the sector average78.38% below the sector average78.38% below the sector average78.38% below the sector average78.38% below the sector average
Operating Profit Loss
72.29% below the market average72.29% below the market average72.29% below the market average72.29% below the market average72.29% below the market average
22.22% below the sector average22.22% below the sector average22.22% below the sector average22.22% below the sector average22.22% below the sector average

Balance Sheet Ratings

The difference between current assets and current liabilities.

A current asset representing the company's financial liquidity.

Assets
51.1% below the market average51.1% below the market average51.1% below the market average51.1% below the market average51.1% below the market average
28.3% below the sector average28.3% below the sector average28.3% below the sector average28.3% below the sector average28.3% below the sector average
Cash
25.45% below the market average25.45% below the market average25.45% below the market average25.45% below the market average25.45% below the market average
18.52% below the sector average18.52% below the sector average18.52% below the sector average18.52% below the sector average18.52% below the sector average

Director Deal Ratings

The cumulative amount of stocks sold by company directors over 1 year

The cumulative amount of stocks bought by company directors over 1 year

Sells 1y Not Available
Buys 1y Not Available

Broker Ratings

The percentage of stockbrokers that rate the company as a Buy

The percentage of stockbrokers that rate the company as a Hold

Brokers Percent Buy Not Available
Brokers Percent Neutral Not Available

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

4basebio Market Data

Currency UK Pounds
Share Price 1,120.00p
Change Today 50.00p
% Change 4.67 %
52 Week High 1,120.00
52 Week Low 500.00
Volume 849
Shares Issued 12.81m
Market Cap £143.42m

4basebio Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
69.94% below the market average69.94% below the market average69.94% below the market average69.94% below the market average69.94% below the market average
32.08% below the sector average32.08% below the sector average32.08% below the sector average32.08% below the sector average32.08% below the sector average
Price Trend
98.16% above the market average98.16% above the market average98.16% above the market average98.16% above the market average98.16% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average
Income Not Available
Growth
34.8% below the market average34.8% below the market average34.8% below the market average34.8% below the market average34.8% below the market average
51.35% below the sector average51.35% below the sector average51.35% below the sector average51.35% below the sector average51.35% below the sector average

4basebio Dividends

No dividends found

Trades for 25-Apr-2024

Time Volume / Share Price
16:36 20 @ 1,120.00p
16:35 20 @ 1,120.00p
16:35 20 @ 1,120.00p
16:14 100 @ 1,100.00p
16:14 100 @ 1,100.00p

4basebio Key Personnel

CEO Heikki Lanckriet
CFO David John Roth

Top of Page